Fosnight described how stigma itself becomes a barrier to care, even though effective diagnostic and treatment options are available. In an interview, Aleece Fosnight, MSPAS, PA-C, CSC-S, CSE, IF, ...
FG-3246 targets CD46 in mCRPC patients, focusing on those who progressed on ARSI without prior taxane therapy. The trial will evaluate FG-3246's safety, efficacy, and pharmacokinetics, alongside ...
A major focus of the discussion is the integration of advanced prostate cancer therapeutics into urology offices. In this episode of Pearls and Perspectives, Amy Pearlman, MD, speaks with Vahan ...
Ensuring consistent diagnostic quality remains critical. In this video, Veeru Kasivisvanathan, MBBS, BSc, FRCS, MSc, PGCert, PhD, discussed findings from the PRIME trial, a multicenter international ...
Several experts share their thoughts on the impact of the gemcitabine intravesical system for BCG-unresponsive NMIBC. On September 9, 2025, the FDA approved the gemcitabine intravesical system ...
Stephen J. Freedland, MD, placed dietary guidance within the broader context of survivorship care. In discussing the links between diet and prostate cancer, Stephen J. Freedland, MD, a professor of ...
Can I charge for different stone procedures in the same kidney?
Can I charge for different stone procedures in the same kidney?
Can I charge for different stone procedures in the same kidney?
Can I charge for different stone procedures in the same kidney?
Can I charge for different stone procedures in the same kidney?
Can I charge for different stone procedures in the same kidney?
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback